DanCann Pharma AS (STU:DAN0) EBITDA Margin %: -59.91% (As of Sep. 2025)


STU:DAN0 DanCann Pharma AS STU:DAN0
27 GF Score
Price €0.00
! 3 Warning Signs
View Full Analysis

What is DanCann Pharma AS EBITDA Margin %?

DanCann Pharma AS STU:DAN0 27 EBITDA Margin % is -59.91% as of Sep. 2025. GuruFocus rates STU:DAN0 with a GF Score™ of 27/100. The stock has 3 warning signs investors should review.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. DanCann Pharma AS's EBITDA for the three months ended in Sep. 2025 was €-0.13 Mil. DanCann Pharma AS's Revenue for the three months ended in Sep. 2025 was €0.22 Mil. Therefore, DanCann Pharma AS's EBITDA margin for the quarter that ended in Sep. 2025 was -59.91%.

DanCann Pharma AS  (STU:DAN0) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

DanCann Pharma AS EBITDA Margin % Related Terms

DanCann Pharma AS EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for DanCann Pharma AS's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DanCann Pharma AS EBITDA Margin % Chart

DanCann Pharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial 0.00 -1,486.44 -226.00 -890.26 -67.30

DanCann Pharma AS Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -48.59 -117.68 -945.45 -186.71 -59.91

STU:DAN0 vs ZTS, UTHR, RGC: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, DanCann Pharma AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DanCann Pharma AS EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DanCann Pharma AS's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where DanCann Pharma AS's EBITDA Margin % falls into.


STU:DAN0
27GF Score
DanCann Pharma AS STU:DAN0
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DanCann Pharma AS EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

DanCann Pharma AS's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-0.669/0.994
=-67.30 %

DanCann Pharma AS's EBITDA Margin % for the quarter that ended in Sep. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=-0.13/0.217
=-59.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -59.91% mean?
DanCann Pharma AS (STU:DAN0) has a EBITDA Margin % of -59.91% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on DanCann Pharma AS and its competitors.
Is DanCann Pharma AS's EBITDA Margin % too high?
DanCann Pharma AS's current EBITDA Margin % is -59.91%. Overall, DanCann Pharma AS has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does DanCann Pharma AS's EBITDA Margin % compare to ZTS and UTHR?
DanCann Pharma AS's EBITDA Margin % of -59.91% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on DanCann Pharma AS and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DanCann Pharma AS's current EBITDA Margin % is -59.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DanCann Pharma AS stock overvalued right now?
DanCann Pharma AS (STU:DAN0) has a current EBITDA Margin % of -59.91%. The current EBITDA Margin % is -59.91%. DanCann Pharma AS's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For DanCann Pharma AS (STU:DAN0), the current EBITDA Margin % is -59.91% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DanCann Pharma AS Business Description

Address Rugvaenget 5, Ansager, DNK, DK-6823
DanCann Pharma AS is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company. The company is focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics for a broad range of diseases.
27GF Score

Get the complete analysis for STU:DAN0

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.00
Price